Journal of Global Infectious Diseases

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 14  |  Issue : 3  |  Page : 99--105

A randomized clinical trial comparing triple therapy versus non-bismuth based quadruple therapy for the eradication of Helicobacter Pylori in Kuwait


Ahmad Alfadhli1, Mohamed Alboraie2, Mostafa Afifi3, Abhijit Dangi1 
1 Haya Al-Habeeb Gastroenterology Center, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait
2 Department of Internal Medicine, Al-Azhar University, Cairo, Egypt
3 Haya Al-Habeeb Gastroenterology Center, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait; Department of Gastroenterology, Lancashire Teaching Hospitals NHS Trust, Chorley, UK

Correspondence Address:
Prof. Mohamed Alboraie
Department of Internal Medicine, Faculty of Medicine, Al-Azhar University, Nasr City 11884, Cairo
Egypt

Introduction: Helicobacter pylori-induced chronic infection is associated with peptic ulcer, chronic gastritis, gastric cancer, and increasing antibiotic resistance. We aimed to evaluate the efficacy of clarithromycin-based triple therapy and non-bismuth based quadruple therapy for eradicating H. pylori in patients with chronic gastritis in Kuwait. Methods: We enrolled a total of 603 treatment-naive dyspeptic patients with gastric biopsy-proven chronic gastritis secondary to H. pylori in a prospective, open-label, randomized study. Patients were randomized into two groups: a group received the standard triple therapy (omeprazole, amoxicillin, and clarithromycin) for 14 days and a group received quadruple therapy (omeprazole, amoxicillin, clarithromycin, and metronidazole) for 14 days. All patients were tested for the eradication of H. pylori by carbon-13 urea breath test 1 month after eradication therapy. Results: The overall eradication rate was 63.2%. The eradication rates in intention-to-treat (ITT) and per protocol (PP) population were 58.4% and 64.6%, respectively, in triple therapy group. In the quadruple therapy group, the eradication rates in ITT and PP population were 68.0% and 78.5%, respectively, with a statistically significant higher eradication rate in patients treated by quadruple therapy than the triple therapy (P < 0.01). Multivariate logistic regression analysis revealed that treatment regimen was the only significant predictor for successful H. pylori eradication. The most common adverse events were abnormal taste, headache, dizziness, and abdominal pain. Conclusion: Non-bismuth based quadruple therapy is more effective than standard clarithromycin-based triple therapy for eradicating H. pylori in patients with chronic gastritis. ClinicalTrials.gov Identifier: NCT04617613


How to cite this article:
Alfadhli A, Alboraie M, Afifi M, Dangi A. A randomized clinical trial comparing triple therapy versus non-bismuth based quadruple therapy for the eradication of Helicobacter Pylori in Kuwait.J Global Infect Dis 2022;14:99-105


How to cite this URL:
Alfadhli A, Alboraie M, Afifi M, Dangi A. A randomized clinical trial comparing triple therapy versus non-bismuth based quadruple therapy for the eradication of Helicobacter Pylori in Kuwait. J Global Infect Dis [serial online] 2022 [cited 2022 Oct 6 ];14:99-105
Available from: https://www.jgid.org/article.asp?issn=0974-777X;year=2022;volume=14;issue=3;spage=99;epage=105;aulast=Alfadhli;type=0